Fate Therapeutics

Biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders.

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Our first-in-class cell therapy product candidates undergoing clinical development today utilize healthy donor cells, which we modify ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function. We are also pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC platform to derive cell therapy product candidates that can be delivered off-the-shelf for the treatment of a large number of patients.

Visit website: https://fatetherapeutics.com/

Fate Therapeutics News

Off-the-shelf natural killer cells to target solid tumours in clinical trial

Medical News Today - 09-Apr-2019

Using iPS cells would be a lot cheaper than personalised immunotherapy

Read more...

Off-the-shelf natural killer cells to target solid tumours in clinical trial

Medical News Today - 09-Apr-2019

Using iPS cells would be a lot cheaper than personalised immunotherapy

Read more...